


This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-33. Cancelled.

- 34. (Original) A method for inhibiting neoplastic cell proliferation in an animal comprising administering to an animal having at least one neoplastic cell present in its body a therapeutically effective amount of the agent of claim 1.
- 35. (Original) A method for inhibiting neoplastic cell proliferation in an animal comprising administering to an animal having at least one neoplastic cell present in its body a therapeutically effective amount of the oligonucleotide of claim 3.
- 36. (Original) The method according to claim 35, wherein the animal is a human.
- 37. (Original) The method according to claim 35, further comprising administering to the animal a therapeutically effective amount of a histone deacetylase small molecule inhibitor with a pharmaceutically acceptable carrier for a therapeutically effective period of time.

38-43. Cancelled.

- 
- 44. (Original) A method for inhibiting cell proliferation in a cell, comprising contacting a cell with at least two reagents selected from the group consisting of an antisense oligonucleotide that inhibits a specific histone deacetylase isoform, a histone deacetylase small molecule inhibitor that inhibits a specific histone deacetylase isoforms, an antisense oligonucleotide that inhibits a DNA methyltransferase, and a DNA methyltransferase small molecule inhibitor.
 - 45. (Original) A method for modulating cell proliferation or differentiation of a cell comprising inhibiting a specific HDAC isoforms that is involved in cell proliferation or differentiation by contacting the cell with an agent of claim 1.
 - 46. (Original) The method according to claim 45, wherein the cell proliferation is neoplasia.
 - 47. (Original) The method according to claim 46, wherein the histone deacetylase isoform is selected from the group consisting of HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-6, HDAC-7 AND HDAC-8.
 - 48. (Original) The method according to claim 47, wherein the histone deacetylase isoform is HDAC-1 and/or HDAC-4.